Allergy Spray Cuts COVID-19 Risk by 70% in German Clinical Trial

Tejal Somvanshi

Allergy sufferers take note: The common nasal spray you use for allergies might also protect against COVID-19!

Photo Source: Kateryna Hliznitsova (Unsplash)

German researchers discovered azelastine nasal spray reduced COVID-19 infections by a remarkable 70% in clinical trials.

Photo Source: Kateryna Hliznitsova (Unsplash)

The study included 450 mostly vaccinated adults who used either azelastine spray or placebo three times daily.

Photo Source: Kateryna Hliznitsova (Unsplash)

Only 2.2% of people using azelastine tested positive for COVID-19, compared to 6.7% in the placebo group.

Photo Source: Kateryna Hliznitsova (Unsplash)

Those using the antihistamine spray who did get infected took longer to become infected - 31 days versus just 19 days for the placebo group.

Photo Source: Kateryna Hliznitsova (Unsplash)

The nasal spray didn't just fight COVID-19 - it reduced overall respiratory infections from 22% to 9.3%, including fewer common colds.

Photo Source: Andrej Lišakov  (Unsplash)

How does it work? Researchers think azelastine might bind to viruses in the nasal passages or block the ACE2 receptor that COVID-19 uses to enter cells.

Photo Source: Kateryna Hliznitsova (Unsplash)

Medical experts caution that using the spray three times daily might be less practical than wearing a mask in high-risk situations.

Photo Source: Andrej Lišakov  (Unsplash)

Dr. Chin-Hong from UCSF emphasized: "Vaccines should remain the primary defense against COVID-19, especially for older adults."

Photo Source: Getty Images (Unsplash)

The spray is available over-the-counter in the US as Astepro Allergy and in Australia, but requires a prescription in the UK.

Photo Source: Tonkla Pairoh (Unsplash)

As COVID cases rise in many areas, this readily available nasal spray might offer an additional tool to reduce infection risk.

Photo Source: Mohammadreza Ghasemian (Unsplash)